Asirvad Micro Finance IPO GMP, Details, Guidance, Subscription Status, allotment @ Chanakyanipothi.com
    👉A legacy of 31 Years.Asirvad Micro Finance IPO
    India`s Oldest Investment & IPO website.
    👉Most Trusted by Investors across India.

    Table of Contents

    Asirvad Micro Finance IPO Sebi nod:
    Indegene ltd  has received Sebi nod to go ahead with its IPO. and now the IPO will open for subscription on 6th May. Listing is expected on 13 May.

    Asirvad Micro Finance IPO Guidance.
    Will update once the price band is announced

    Asirvad Micro Finance IPO Grey Market Premium  
    The IPO is expected to enjoy strong fancy in the grey market at present. For latest updates of GMP, click

    Asirvad Micro Finance IPO Subscription Status 
    Will update once the IPO opens

    Asirvad Micro Finance IPO Promoters
    The company is a professionally managed company and does not have an identifiable promoter.

    Asirvad Micro Finance IPO Company Details to watch

    Indegene is a “digital-first” commercialization company focused exclusively on the global life sciences industry. Its solutions enable biopharmaceutical, emerging biotech and medical devices companies develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. It achieves this by combining over two decades of healthcare domain expertise and fit-for-purpose technology. Its portfolio of solutions cover all aspects of commercial, medical, regulatory and R&D operations of life sciences companies.
    It has established client relationships with 19 of the 20 largest biopharmaceutical companies in the world by revenue for the Financial Year 2021, having earned more than 70.00% of its total revenue from continuing operations for each of the Financial Years 2022, 2021 and 2020 from these 19 customers. As of June 30, 2022, it had a total of 52 active clients (i.e., clients from whom it earned US$0.25 million or more in revenues during the 12 months preceding the relevant date). It had 21 clients from whom it earned between US$1 million and US$10 million in revenues, three clients from whom it earned between US$10 million and US$25 million in revenues, and four clients from whom it earned more than US$25 million in revenues, during the 12 months ended June 30, 2022.

    Given the breadth of its solutions, it believes that it is well positioned to benefit from the expected growth in life sciences operations expenditure, which was estimated at Rs.11.3 trillion (US$146 billion) in 2021 and is expected to grow at a CAGR of 6.3% to reach Rs.14.4 trillion (US$187 billion) in 2025. Sales and marketing was the largest segment of life sciences operations expenditure, contributing Rs.4.1 trillion (US$53 billion) or 36% of overall life sciences operations expenditure, but with a low outsourcing penetration rate of 7-12%. However, outsourcing expenditure in this segment is projected to grow at a CAGR of 11.3% between 2021 and 2025, representing room for growth. It has already penetrated this segment through its Enterprise Commercial Solutions and derived Rs.10,161.57 million or 61.04% of the revenue from operations for the Financial Year 2022 from this segment.
    As of June 30, 2022, it had 52 active clients. It delivers solutions to them from its operation hubs located across North America, Europe and Asia. it has internally developed artificial intelligence (“AI”) and machine learning (“ML”) based proprietary platforms, which allows it to offer its solutions across the globe at scale. Its delivery model allows it to operate where its clients are located. As of June 30, 2022, it had 5,245 full-time employees across nine countries, of which 4,712 employees were delivery employees (i.e., employees who do not belong to corporate and support functions). As of June 30, 2022, 21.88% of its delivery employees had healthcare-related educational backgrounds.

    For more information about the company, click 

    Objects of the IPO
    This is fresh issue of capital & offer for sale.
    The Company proposes to utilise the Net Proceeds towards funding of the following objects:
    1. Repayment/prepayment of indebtedness of one of its Subsidiaries, ILSL Holdings, Inc.;
    2. Funding the capital expenditure requirements of its Company and our Material Subsidiary, Indegene, Inc.;
    3. Payment of consideration towards acquisition of additional shares in DT Associates Limited by ILSL
    Holdings, Inc., a Subsidiary; and
    4. General corporate purposes and inorganic growth

    Asirvad Micro Finance IPO Details to watch.
    IPO opens on  6 May 2024
    IPO closes on  8 May 2024
    Issue Type Book Built Issue IPO
    Issue Size up to 40746891 Shares /
    Rs 1841.76 Crore
    * Fresh Issue 16814159 Shares/
    Rs. 760 Crore
    * Offer for Sale  23932732 Shares/ Rs. 1081.76 Crore
    Employees Discount Rs.30
    Face Value per share: Rs. 2
       
    Price Band Rs. 430-452
    Employee discount  Rs. 0 per share
    Retail Lot Size  33 Shares
    Listing will at  BSE, NSE
    Shares offered to Shares Rs. in Cr
    QIB (50 %) 
    NII (15 %) 
    RII (35 %) 
    Employees 
    Total Shares 
    Retail portion will be oversubscribed by  (?) Forms
    How much Shares to Apply? Rs.
    Min Retail Application 33 Shares     14916
    Max Retail Application  429 shares   193908
    Small HNI (Min) application  462 Shares   208824
    Small HNI (Max) application 2211 shares   999372
    Big HNI Application 2244 shares 1014288

    Asirvad Micro Finance IPO GMP Details to watch Guidance & Subscription

    Asirvad Micro Finance IPO Indicative timetable
    IPO opens on   6 May 2024
    IPO Closes on   8 May 2024
    IPO Allotment on    9 May 2024
    Unblocking of ASBA  10 May 2024
    Credit to Demat Accounts  10 May 2024
    Listing on 13 May 2024
    Registered Office of INDEGENE
    Aspen Block G4, 3rdFloor, Manyata Embassy Business Park, Outer Ring Road, Nagawara, Bengaluru 560045, Karnataka, India
    INDEGENE IPO Lead Managers 
    Kotak Mahindra Capital Company Ltd
    Citigroup Global Markets India Pvt ltd
    J.P. Morgan India Pvt ltd
    Nomura Financial Advisory and Securities (India) Pvt ltd
    Registrar to INDEGENE IPO
    Link Intime India Pvt. Ltd
    INDEGENE IPO Financial & Analytical Ratios
    Year Total Income Net Profit EPS RoNW
      Rs. in Cr. Rs.in Cr. Rs. %
    2020-21 996.92 186 7.56 46.04
    2021-22 1690.50 163 7.50 21.57
    2022-23 (3M) 2364 266 12.03 25.02
    Book Value of the Share on 31.03.2023 Rs.48.10    
    Book Value of the Share after the IPO Rs.?    
    Offer Price   Rs. 452    
    Ratio Analysis
    Upper Price Band/last EPS 37.57
    Upper offer price/Book Value Ratio 9.40
    Upper offer price/BV after IPO Ratio

    INDEGENE Peer Comparison
    There are no listed companies in India and globally that are of comparable size, from the same industry and with similar business model as that of the Company.

    # This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.

    INDEGENE IPO GMP Details to watch Guidance & Subscription

    Quicklinks

     

    Asirvad Micro Finance IPO GMP Guidance

    Leave a Reply

    Your email address will not be published. Required fields are marked *